Evaluation of the adrenergic effects of a novel optically active catecholamidine in vitro and in vivo: differential application of the Easson-Stedman hypothesis to alpha and beta adrenoceptors.
D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D002395:Catecholamines / Q000494:pharmacology; D006168:Guinea Pigs; D006339:Heart Rate / Q000187:drug effects; D008297:Male; D008954:Models, Biological; D010643:Phenoxybenzamine / Q000494:pharmacology; D011311:Pressoreceptors / Q000187:drug effects; D011433:Propranolol / Q000494:pharmacology; D011941:Receptors, Adrenergic / Q000187:drug effects*; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects; D011943:Receptors, Adrenergic, beta / Q000187:drug effects; D012110:Reserpine / Q000494:pharmacology; D013237:Stereoisomerism
C038834:3,4,alpha-trihydroxyphenylacetamidine; D002395:Catecholamines; D011941:Receptors, Adrenergic; D011942:Receptors, Adrenergic, alpha; D011943:Receptors, Adrenergic, beta; D010643:Phenoxybenzamine; D000804:Angiotensin II; C038835:3,4-dihydroxyphenylacetamidine; D012110:Reserpine; D011433:Propranolol